See more : China Minsheng Banking Corp., Ltd. (CMAKY) Income Statement Analysis – Financial Results
Complete financial analysis of Orgenesis Inc. (ORGS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orgenesis Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Guangzhou Grandbuy Co., Ltd. (002187.SZ) Income Statement Analysis – Financial Results
- Northern Electric PLC (NTEA.L) Income Statement Analysis – Financial Results
- AmRest Holdings SE (EAT.MC) Income Statement Analysis – Financial Results
- $ Attika Group (53W.SI) Income Statement Analysis – Financial Results
- Odlewnie Polskie S.A. (ODL.WA) Income Statement Analysis – Financial Results
Orgenesis Inc. (ORGS)
About Orgenesis Inc.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 530.00K | 36.03M | 35.50M | 7.65M | 33.26M | 18.66M | 10.09M | 6.40M | 2.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.26M | 20.44M | 28.16M | 30.62M | 18.12M | 10.70M | 6.81M | 7.66M | 3.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00 |
| Gross Profit | -5.73M | 15.59M | 7.34M | -22.97M | 15.14M | 7.96M | 3.28M | -1.26M | -906.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -500.00 |
| Gross Profit Ratio | -1,080.19% | 43.26% | 20.68% | -300.13% | 45.53% | 42.65% | 32.53% | -19.70% | -30.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.09M | 6.01M | 36.64M | 83.99M | 12.46M | 6.46M | 2.48M | 2.16M | 1.07M | 1.69M | 1.64M | 2.31M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 34.62M | 16.16M | 15.40M | 19.35M | 25.25M | 16.61M | 10.69M | 6.45M | 4.04M | 2.88M | 3.82M | 2.68M | 72.35K | 21.17K | 25.65K | 0.00 |
| Selling & Marketing | 464.00K | -566.00K | -687.00K | -380.00K | 1.15M | 1.21M | 599.00K | 397.00K | 326.00K | 144.00K | 187.83K | 140.94K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.62M | 16.16M | 14.71M | 18.97M | 25.25M | 16.61M | 10.69M | 6.45M | 4.04M | 2.88M | 3.82M | 2.68M | 72.35K | 21.17K | 25.65K | 3.00K |
| Other Expenses | 0.00 | 788.00K | -1.33M | 474.00K | 2.04M | -1.02M | 1.63M | 2.12M | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K |
| Operating Expenses | 45.76M | 22.95M | 50.02M | 103.43M | 39.74M | 22.06M | 14.80M | 10.23M | 6.31M | 4.58M | 5.46M | 4.99M | 72.35K | 21.17K | 25.65K | 3.00K |
| Cost & Expenses | 52.01M | 43.39M | 50.02M | 103.43M | 57.86M | 32.75M | 21.60M | 17.88M | 10.19M | 4.58M | 5.46M | 4.99M | 72.35K | 21.17K | 25.65K | 3.50K |
| Interest Income | 0.00 | 1.82M | 943.00K | 1.25M | 498.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.17M | 1.82M | 1.29M | 1.06M | 461.00K | 2.75M | 1.23M | 689.00K | 696.00K | 691.09K | 172.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.56M | 1.98M | 1.86M | 1.44M | 3.81M | 2.62M | 2.60M | 2.92M | 1.99M | 4.55K | 3.26K | 1.41K | 0.00 | 15.00K | 0.00 | 0.00 |
| EBITDA | -60.72M | -8.30M | -15.72M | -94.21M | -18.91M | -12.39M | -9.85M | -9.04M | -2.64M | -4.80M | -5.36M | -5.00M | -72.35K | -6.17K | -25.65K | -3.50K |
| EBITDA Ratio | -11,456.23% | -19.15% | -39.00% | -1,244.08% | -62.73% | -65.47% | -100.96% | -135.77% | -175.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -53.64M | -7.37M | -42.68M | -95.78M | -24.60M | -14.65M | -11.23M | 11.28M | -7.21M | -4.58M | -5.46M | -4.99M | -72.35K | -21.17K | -25.65K | -3.50K |
| Operating Income Ratio | -10,120.00% | -20.45% | -120.22% | -1,251.71% | -73.98% | -78.53% | -111.31% | 176.29% | -242.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.81M | -1.85M | -1.15M | -1.63M | -47.00K | -2.83M | -3.66M | -1.26M | 1.85M | -927.10K | -78.66K | -519.21K | 0.00 | -15.00K | 0.00 | 0.00 |
| Income Before Tax | -64.44M | -11.96M | -17.95M | -96.74M | -25.48M | -17.77M | -13.68M | -10.74M | -5.36M | -5.50M | -5.54M | -5.00M | -72.35K | -36.17K | -25.65K | -3.50K |
| Income Before Tax Ratio | -12,159.43% | -33.20% | -50.56% | -1,264.19% | -76.61% | -95.24% | -135.56% | -167.91% | -180.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 473.00K | 209.00K | 108.00K | -1.61M | 563.00K | 1.34M | -1.31M | -1.55M | -900.00K | 691.09K | 172.51K | 9.58K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -55.36M | -12.17M | -18.06M | -95.13M | -26.04M | -18.29M | -12.37M | -9.19M | -4.46M | -5.50M | -5.54M | -5.00M | -72.35K | -36.17K | -25.65K | -3.50K |
| Net Income Ratio | -10,445.47% | -33.78% | -50.87% | -1,243.17% | -78.30% | -98.05% | -122.58% | -143.72% | -150.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.91 | -0.48 | -0.74 | -4.46 | -1.64 | -1.37 | -1.28 | -1.08 | -0.96 | -1.22 | -1.32 | -1.11 | -0.01 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | -1.91 | -0.48 | -0.74 | -4.46 | -1.64 | -1.37 | -1.27 | -1.08 | -0.94 | -1.21 | -1.32 | -1.11 | -0.01 | -0.01 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 29.01M | 25.10M | 24.27M | 21.32M | 15.91M | 13.37M | 9.68M | 8.52M | 4.65M | 4.51M | 4.20M | 4.52M | 6.71M | 6.71M | 6.71M | 6.71M |
| Weighted Avg Shares Out (Dil) | 29.01M | 25.10M | 24.27M | 21.32M | 15.91M | 13.37M | 9.71M | 8.52M | 4.74M | 4.56M | 4.21M | 4.52M | 6.71M | 6.71M | 6.71M | 6.71M |
Orgenesis. (ORGS) CEO Vered Caplan on Q4 2020 Results - Earnings Call Transcript
Orgenesis. (ORGS) CEO Vered Caplan on Q4 2020 Results - Earnings Call Transcript
Orgenesis leads the charge at an exciting time for cell and gene therapy
Global biotech unlocking the potential of personalized therapies and closed processing systems helpful in manufacturing Maryland-based firm has a Cell and Gene Therapy (CGT) Biotech platform The platform consists of three core elements: POCare Therapeutics, POCare Technologies, and POCare Network...
Orgenesis teams with Dong-a University Hospital in South Korea and Cure Therapeutics to utilize its Mobile Processing Units and Labs, or OMPULs
Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) announced Monday it has signed a collaboration agreement with Dong-a University Hospital in South Korea and Cure Therapeutics Inc to utilize Orgenesis Mobile Processing Units and Labs (OMPULs). The company said the teams will align to use...
Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Therapeutics in South Korea
GERMANTOWN, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), Dong-a University Hospital in South Korea, and Cure...
Orgenesis Schedules Fiscal 2020 Year-End Business Update Conference Call
GERMANTOWN, Md., March 04, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it plans to host a conference...
Orgenesis: A Cell And Gene Therapy Disruptor With A Nice Risk Reward Profile
Orgenesis is a $151m market cap biotech focused on cell and gene therapy technologies. It has a technology, therapeutics, and point of care platform that enables its CGT partners to develop products in a safe and sterile environment near to...
Orgenesis Third Quarter 2020 Revenue Increases 40% Reflecting Continued Progress of POCare Platform
Reports rapid advancement of therapeutic pipeline
Orgenesis Announces Virtual 2020 Annual Meeting of Stockholders
GERMANTOWN, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, announced today that due to the public health impact...
Vetter Continues Its Long-term Investment Strategy to Sustain Future Growth
Vetter, a globally leading contract development and manufacturing organization (CDMO), has moved into its new headquarters in Ravensburg, Germany. The
Investissement climatique : si ce n'est pas maintenant, quand ? Si ce n'est pas vous, qui ? - Actualités Asset Management
Parmi les nombreux défis environnementaux, sociaux et de gouvernance (ESG) auxquels les entreprises sont aujourd’hui confrontées, il en est un qui éclipse tous les autres par son urgence....
Source: https://incomestatements.info
Category: Stock Reports